Biofrontera Inc.
BFRI
Positions held
Your positionsBFRI isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $13.65M | Enterprise value | $16.48M | Trailing P/E | — | Forward P/E | 2.14 |
| PEG | — | Price / book | 2.19 | Beta | 0.88 | Dividend yield | 0.00% |
| Revenue growth | 32.9% | Earnings growth | — | Gross margin | 79.3% | Operating margin | -4.4% |
| Profit margin | -13.8% | ROE | -9.9% | ROA | -17.4% | Debt / equity | 1.26 |
| Current ratio | 1.18 | Free cash flow | -$7.60M | Analyst recommendation | none | Mean target | $6.00 |
| 52w high | $1.66 | 52w low | $0.56 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $12.0M | $10.1M | $17.1M | $7.0M | $9.0M | — |
| Op margin | -4.4% | -39.0% | 26.7% | -89.8% | -56.2% | — |
| Net income | -$0.6M | -$4.8M | $5.6M | -$6.6M | -$5.3M | — |
| Gross margin | 79.9% | 79.0% | 82.4% | 70.7% | 70.7% | — |
| Gross profit | $9.6M | $8.0M | $14.1M | $4.9M | $6.4M | — |
| Operating income | -$0.5M | -$3.9M | $4.6M | -$6.3M | -$5.1M | — |
- Revenue +19% vs prior quarter ($12M vs $10M).
- Gross margin 79.9% (was 79% prior quarter).
- Operating margin expanded to -4.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $41.7M | $37.3M | $34.1M | $28.7M | — |
| Op margin | -27.2% | -46.1% | -66.3% | -78.1% | — |
| Net income | -$10.5M | -$17.8M | -$20.1M | -$0.6M | — |
| Gross margin | 73.7% | 50.1% | 48.8% | 47.0% | — |
| Gross profit | $30.7M | $18.7M | $16.6M | $13.5M | — |
| Operating income | -$11.3M | -$17.2M | -$22.6M | -$22.4M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-14 · Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
2026-08-20 · Biofrontera (BFRI) Q2 2026 Earnings Call Transcript
2026-08-14 · Biofrontera Inc. Q2 2026 Earnings Call Summary
2026-08-13 · Biofrontera Inc (BFRI) (Q2 2026) Earnings Call Highlights: Strong Ameluz Growth Drives Revenue ...
2026-08-13 · Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates
2026-08-13 · Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth
2026-08-12 · Earnings To Watch: Biofrontera Inc (BFRI) Q2 2026 -- GF Value Sees 51% Downside
2026-08-05 · Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026
Price (daily)
Full chart · RSI · MACD · patterns